U.S. Markets close in 2 hrs 59 mins
  • S&P 500

    3,675.72
    +6.71 (+0.18%)
     
  • Dow 30

    30,071.66
    +187.87 (+0.63%)
     
  • Nasdaq

    12,405.10
    +55.73 (+0.45%)
     
  • Russell 2000

    1,858.32
    +20.29 (+1.10%)
     
  • Crude Oil

    45.82
    +0.54 (+1.19%)
     
  • Gold

    1,840.50
    +10.30 (+0.56%)
     
  • Silver

    24.10
    +0.02 (+0.08%)
     
  • EUR/USD

    1.2149
    +0.0034 (+0.2794%)
     
  • 10-Yr Bond

    0.9200
    -0.0280 (-2.95%)
     
  • Vix

    21.06
    -0.11 (-0.52%)
     
  • GBP/USD

    1.3486
    +0.0111 (+0.8267%)
     
  • USD/JPY

    103.8760
    -0.5480 (-0.5248%)
     
  • BTC-USD

    19,313.34
    +364.44 (+1.92%)
     
  • CMC Crypto 200

    379.89
    +5.48 (+1.46%)
     
  • FTSE 100

    6,490.27
    +26.88 (+0.42%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

GNFT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / May 12, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Genfit SA ("Genfit" or "the Company") (GNFT). Investors who purchased Genfit securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/gnft.

The investigation concerns whether Genfit and certain of its officers and/or directors have violated federal securities laws.

On May 11, 2020, it was revealed that Genfit's hepatitis treatment failed in a Phase 3 test. Investor's Business Daily reported that "Genfit tested a drug called elafibranor in patients with nonalcoholic steatohepatitis, or NASH. However, the hepatitis treatment failed to resolve the symptoms of NASH without leading to worsening fibrosis." Following this news, Genfit stock dropped over 50% during after-hours trading.

If you are aware of any facts relating to this investigation, or purchased Genfit shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/gnft. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/589462/GNFT-Investor-Alert-Bronstein-Gewirtz-Grossman-LLC-Announces-Investigation-of-Genfit-SA-and-Encourages-Investors-to-Contact-the-Firm